{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:33:10Z","timestamp":1772753590389,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.molimm.2020.09.013","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T01:55:20Z","timestamp":1601517320000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Quantum biochemistry in cancer immunotherapy: New insights about CTLA-4\/ipilimumab and design of ipilimumab-derived peptides with high potential in cancer treatment"],"prefix":"10.1016","volume":"127","author":[{"given":"Jackson L.","family":"Amaral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel J.M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro F.N.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo A.","family":"de Morais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"F.F.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernandes F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valder N.","family":"Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2020.09.013_bib0005","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1021\/acs.jmedchem.8b00541","article-title":"Structure-function analysis of immune checkpoint receptors to guide emerging anticancer immunotherapy","volume":"61","author":"Ac\u00farcio","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molimm.2020.09.013_bib0010","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3389\/fimmu.2017.01751","article-title":"Progress and challenges in the design and clinical development of antibodies for Cancer therapy","volume":"8","author":"Almagro","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2020.09.013_bib0015","doi-asserted-by":"crossref","first-page":"183228","DOI":"10.1016\/j.bbamem.2020.183228","article-title":"Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin","author":"Arias","year":"2020","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.molimm.2020.09.013_bib0020","doi-asserted-by":"crossref","first-page":"184105","DOI":"10.1063\/1.1897382","article-title":"An efficient approach for ab initio energy calculation of biopolymers","volume":"122","author":"Chen","year":"2005","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.molimm.2020.09.013_bib0025","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.1063\/1.1316015","article-title":"From molecules to solids with the DMol3 approach","volume":"113","author":"Delley","year":"2000","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.molimm.2020.09.013_bib0030","doi-asserted-by":"crossref","first-page":"W665","DOI":"10.1093\/nar\/gkh381","article-title":"PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations","volume":"32","author":"Dolinsky","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molimm.2020.09.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molimm.2020.09.013_bib0040","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/nar\/gkg563","article-title":"ExPASy: the proteomics server for in-depth protein knowledge and analysis","volume":"31","author":"Gasteiger","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molimm.2020.09.013_bib0045","series-title":"Protein Identification and Analysis Tools in the ExPASy Server","author":"Gasteiger","year":"2007"},{"key":"10.1016\/j.molimm.2020.09.013_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24112071","article-title":"Development of the inhibitors that target the PD-1\/PD-L1 Interaction-A brief look at progress on small molecules, peptides and macrocycles","volume":"24","author":"Guzik","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.molimm.2020.09.013_bib0055","doi-asserted-by":"crossref","first-page":"67129","DOI":"10.18632\/oncotarget.18004","article-title":"Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.molimm.2020.09.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1063\/1.1849132","article-title":"A new method for direct calculation of total energy of protein","volume":"122","author":"He","year":"2005","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.molimm.2020.09.013_bib0065","first-page":"37","article-title":"Molecular dynamics simulations: advances and applications","volume":"8","author":"Hospital","year":"2015","journal-title":"Adv. Appl. Bioinform. Chem."},{"key":"10.1016\/j.molimm.2020.09.013_bib0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.molimm.2020.09.013_bib0075","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/anie.201710407","article-title":"Immune checkpoint PD-1\/PD-L1: is there life beyond antibodies? Angew","volume":"57","author":"Konstantinidou","year":"2018","journal-title":"Chem. Int. Ed. Engl."},{"key":"10.1016\/j.molimm.2020.09.013_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.molimm.2020.09.013_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13354","article-title":"Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy","volume":"7","author":"Lee","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molimm.2020.09.013_bib0090","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1039\/C9CP06530J","article-title":"The urokinase plasminogen activator binding to its receptor: A quantum biochemistry description within an in\/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors","volume":"22","author":"Morais","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.molimm.2020.09.013_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: consistent treatment of internal and surface residues in empirical p K a predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.molimm.2020.09.013_bib0100","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.molimm.2020.09.013_bib0105","doi-asserted-by":"crossref","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","article-title":"Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab","volume":"114","author":"Ramagopal","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2020.09.013_bib0110","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","article-title":"Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex","volume":"410","author":"Schwartz","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2020.09.013_bib0115","doi-asserted-by":"crossref","first-page":"11017","DOI":"10.1200\/JCO.2019.37.15_suppl.11017","article-title":"A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST)","volume":"37","author":"Singh","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2020.09.013_bib0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijbiomac.2020.07.174","article-title":"A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor","volume":"164","author":"Souza","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.molimm.2020.09.013_bib0125","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2020.09.013_bib0130","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41598-018-20325-0","article-title":"Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry","volume":"8","author":"Tavares","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molimm.2020.09.013_bib0135","doi-asserted-by":"crossref","first-page":"W473","DOI":"10.1093\/nar\/gkm423","article-title":"PIC: protein interactions calculator","volume":"35","author":"Tina","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molimm.2020.09.013_bib0140","series-title":"WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.molimm.2020.09.013_bib0145","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1529\/biophysj.106.099150","article-title":"Quantum and molecular dynamics study for binding of macrocyclic inhibitors to human \u03b1-thrombin","volume":"92","author":"Wu","year":"2007","journal-title":"Biophys. J."},{"key":"10.1016\/j.molimm.2020.09.013_bib0150","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1063\/1.1591727","article-title":"Molecular fractionation with conjugate caps for full quantum mechanical calculation of protein-molecule interaction energy","volume":"119","author":"Zhang","year":"2003","journal-title":"J. Chem. Phys."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589020304892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589020304892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:37:23Z","timestamp":1758980243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589020304892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"alternative-id":["S0161589020304892"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2020.09.013","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantum biochemistry in cancer immunotherapy: New insights about CTLA-4\/ipilimumab and design of ipilimumab-derived peptides with high potential in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}